TQR.F Beijing Tong Ren Tang Chinese Medicine Company Limited
- Market cap
- EUR 513M
- P/E
- 12.1x
- P/B
- 1.11x
- ROE
- 9.5%
- Dividend yield
- 6.70%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is TQR.F undervalued?
Graham numberTQR.F trades 22.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Tong Ren Tang Chinese Medicine Company Limited fundamental analysis
No fundamental analysis for Beijing Tong Ren Tang Chinese Medicine Company Limited yet.
Beijing Tong Ren Tang Chinese Medicine Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Tong Ren Tang Chinese Medicine Company Limited
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine products to wholesalers and individuals. It operates through Hong Kong, Mainland China, and Overseas segments. The company also offers Chinese medical consultation and treatment services. It markets its products under the Tong Ren Tang brand name. It also operates retail outlets in Hong Kong and …
Full company profileBeijing Tong Ren Tang Chinese Medicine Company Limited financial statements
Beijing Tong Ren Tang Chinese Medicine Company Limited annual financial statements (HKD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.08B | 1.27B | 1.51B | 1.43B | 1.32B | 1.56B | 1.73B | 1.52B | 1.61B | 1.51B |
| Gross Profit | 795M | 916M | 1.08B | 1.01B | 953M | 1.12B | 1.15B | 1.05B | 1.07B | 926M |
| Operating Income | 527M | 598M | 698M | 652M | 669M | 786M | 818M | 639M | 574M | 536M |
| EBITDA | - | 638M | 752M | 773M | 690M | 783M | 906M | 776M | 724M | 609M |
| Net Income | 420M | 490M | 581M | 556M | 542M | 608M | 646M | 540M | 500M | 397M |
| EPS | - | 0.59 | 0.69 | 0.66 | 0.65 | 0.73 | 0.77 | 0.65 | 0.60 | 0.47 |
| Balance Sheet | ||||||||||
| Total Assets | 2.35B | 2.76B | 3.17B | 3.14B | 3.42B | 3.83B | 4.23B | 4.43B | 4.56B | 4.66B |
| Total Liabilities | 128M | 152M | 147M | 373M | 287M | 295M | 486M | 414M | 313M | 292M |
| Shareholders' Equity | 2.12B | 2.49B | 2.91B | 2.66B | 3.02B | 3.42B | 3.60B | 3.87B | 4.08B | 4.19B |
| Cash & Short-term Investments | 798M | 750M | 550M | 1.06B | 1.43B | 1.66B | 1.99B | 1,000M | 1.77B | 2.23B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 468M | 469M | 578M | 551M | 116M | 777M | 547M | 461M | -217M | 830M |
| Capital Expenditure | 38.3M | 34.1M | 53.2M | 17.0M | 12.9M | 23.4M | 38.5M | 21.9M | 43.2M | 41.2M |
| Free Cash Flow | - | 435M | 524M | 534M | 103M | 754M | 509M | 439M | -260M | 788M |
| Ratios | ||||||||||
| ROE | 19.8% | 19.7% | 20.0% | 20.9% | 18.0% | 17.8% | 17.9% | 14.0% | 12.3% | 9.5% |
| ROA | 17.8% | 17.7% | 18.3% | 17.7% | 15.9% | 15.8% | 15.3% | 12.2% | 11.0% | 8.5% |
| Net Profit Margin | 38.8% | 38.7% | 38.4% | 38.8% | 41.2% | 39.1% | 37.3% | 35.4% | 31.0% | 26.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Beijing Tong Ren Tang Chinese Medicine Company Limited dividends
- Dividend yield
- 6.70%
- Forward dividend
- 0.04 EUR
- Payout ratio
- 73.8%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | HKD 293M | 0.35 | 73.8% |
| 2024 | HKD 276M | 0.33 | 55.2% |
| 2023 | HKD 276M | 0.33 | 51.1% |
| 2022 | HKD 444M | 0.53 | 68.7% |
| 2021 | HKD 201M | 0.24 | 33.1% |
| 2020 | HKD 193M | 0.23 | 35.5% |
| 2019 | EUR 193M | 0.23 | 34.6% |
| 2018 | EUR 159M | 0.19 | 27.4% |
| 2017 | EUR 134M | 0.16 | 27.3% |
| 2016 | EUR 109M | - | 25.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Beijing Tong Ren Tang Chinese Medicine Company Limited
- Insiders 71.68%
- Institutions 2.92%
- Public & others 25.40%
- Shares outstanding 837M
- Free float 237M
Beijing Tong Ren Tang Chinese Medicine Company Limited company profile
- Company name
- Beijing Tong Ren Tang Chinese Medicine Company Limited
- Ticker
- TQR.F
- ISIN
- HK0000145638
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 763
- Fiscal year end
- December
- Address
- Office Tower, Convention Plaza, Wan Chai, Hong Kong
- Phone
- 852 2881 7989
- Website
- cm.tongrentang.com
About Beijing Tong Ren Tang Chinese Medicine Company Limited
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine products to wholesalers and individuals. It operates through Hong Kong, Mainland China, and Overseas segments. The company also offers Chinese medical consultation and treatment services. It markets its products under the Tong Ren Tang brand name. It also operates retail outlets in Hong Kong and in other countries and regions in Asia, the Oceania, North America, and Europe. The company was founded in 1669 and is based in Wan Chai, Hong Kong.
Beijing Tong Ren Tang Chinese Medicine Company Limited management
5- Mr. Han YanExecutive Chairman · born 1979
- Mr. Wang ChiCEO & Executive Director · born 1976
- Mr. Zheng YueExecutive Vice Chairman · born 1974
- Ms. Fung Yi TsangCFO & Company Secretary · born 1977
- Ms. Shaochen QuGeneral Counsel · born 1985